Skip to main content
LUYAN PHARMA CO.,LTD logo

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 ISIN · CNE1000025W1 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-04-24 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
2016年度高级管理人员薪酬与考核管理制度（2016年4月）
Remuneration Information Classification · 95% confidence The document is titled '2016年度高级管理人员薪酬与考核管理制度' which translates to '2016 Annual Senior Management Compensation and Assessment Management System'. It details the principles, scope, salary structure, and performance assessment criteria for senior management personnel. The content focuses on remuneration policies and management rather than financial results, governance structure, or regulatory announcements. It is a detailed report on remuneration management, which aligns with the definition of Remuneration Information (DEF 14A). The document is not an announcement or a brief summary but a substantive policy document on executive compensation.
2016-04-24 Chinese
2015年年度审计报告
Regulatory Filings
2016-04-24 Chinese
2015年度董事会报告
Management Reports Classification · 95% confidence The document is titled as the "2015年度董事会报告" (2015 Annual Board Report) of 鹭燕（福建）药业股份有限公司. It contains detailed information about the board of directors' activities, committee work, governance, company operations, financial performance, and future plans for the year 2015. The content includes comprehensive financial data such as total assets, liabilities, equity, revenue, profit, and detailed breakdowns of business segments and customers. It also discusses governance practices, audit committee activities, and strategic plans. The length of the document (over 14,000 characters) and the depth of financial and operational information indicate it is a full management report rather than a brief announcement or certification. The document is not a transcript, proxy statement, or a simple announcement but a detailed annual report from the board. Therefore, the most appropriate classification is "Management Reports (MDA)" as it provides management's detailed explanation of financial results, business trends, and outlook for the company for the year 2015.
2016-04-24 Chinese
关于召开公司2015年年度股东大会的通知（已取消）
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2015 Annual General Meeting (AGM) of 鹭燕（福建）药业股份有限公司, including the date, time, venue, agenda items to be discussed, voting procedures (both in-person and online), registration methods, and proxy forms. It does not contain the actual annual report, financial statements, or results of the meeting. Instead, it serves as an official announcement to shareholders about the upcoming AGM and how to participate. The document length is 5723 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2016-04-24 Chinese
2015年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2015 年年度报告全文" which translates to "2015 Annual Report Full Text" for 鹭燕（福建）药业股份有限公司. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, corporate governance, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial figures, business overview, risk factors, and corporate governance information, all characteristic of a full Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification document. Therefore, the document fits the definition of an Annual Report (10-K).
2016-04-24 Chinese
独立董事关于第三届十五次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's 15th board meeting of the third session, held on April 22, 2016. It covers topics such as the 2015 profit distribution plan, reappointment of the audit firm for 2016, bank credit guarantees, internal control self-evaluation for 2015, related party fund occupation, and senior management remuneration plans. The document is a formal opinion letter from independent directors rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit results but rather expresses independent opinions on board meeting agenda items. This type of document fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent director opinions on governance and management issues.
2016-04-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.